Cariprazine for schizophrenia and bipolar I disorder: as a dopamine D3-preferring D3/D2 partial agonist, cariprazine offers an alternative to antipsychotics that preferentially modulate D2 receptors.
Despite numerous developments in pharmacotherapeutics, people with schizophrenia or bipolar disorder continue to struggle with residual symptoms or endure treatments that produce adverse effects (AEs). In particular, metabolic issues, sedation, and cognitive impairment plague many current treatment options for these disorders.
Receptor blocking. As a dopamine D3-preferring D3/D2 partial agonist, cariprazine offers an alternative to antipsychotics that preferentially modulate D2 receptors. First-generation (typical) antipsychotics block D2 receptors; atypical antipsychotics block D2 receptors and 5-HT2A receptors. Dopamine partial agonists aripiprazole and brexpiprazole are D2-preferring, with minimal D3 effects. In contrast, cariprazine has a 6-fold to 8-fold higher affinity for D3 receptors than for D2 receptors, and has specificity for the D3 receptor that is 3 to 10 times higher than what aripiprazole has for the D3 receptor3-5 (Table 2, page 37).
Use in schizophrenia. Recommended dosage range is 1.5 to 6 mg/d. In Phase-Ill clinical trials, dosages of 3 to 9 mg/d produced significant improvement on the Positive and Negative Symptom Scale (PANSS) and on the Clinical Global Impression scale. Higher dosages (6 to 9 mg/d) showed early separation from placebo--by the end of Week 1--but carried a dosage-related risk of AEs, leading the FDA to recommend 6 mg/d as the maximum dosage. (1,6-8)
Use in manic or mixed episodes of BD I.
Recommended dosage range is 3 to 6 mg/d. In clinical trials, dosages in the range of 3 to 12 mg/d were effective for acute manic or mixed symptoms; significant improvement in the Young Mania Rating Scale (YMRS) score was seen as early as Day 4. Dosages >6 mg/d yielded no additional benefit and were associated with increased risk of AEs. (9,12)
Pharmacologic profile, adverse effects.
Cariprazine has a pharmacologic profile consistent with the generally favorable metabolic profile and lack of anticholinergic effects seen in clinical trials. In short-and long-term trials, the drug had minimal effects on prolactin, blood pressure, and cardiac conduction. (13)
Across clinical trials for both disorders, akathisia and parkinsonism were among more common AEs of cariprazine. Both AEs were usually mild, resulting in relatively few premature discontinuations from trials. Parkinsonism appeared somewhat dosage-related; akathisia had no clear relationship to dosage.
How it works
The theory behind the use of partial agonists, including cariprazine, is that these agents restore homeostatic balance to neurochemical circuits by:
* decreasing the effects of endogenous neurotransmitters (dopamine tone) in regions of the brain where their transmission is excessive, such as mesolimbic regions in schizophrenia or mania
* simultaneously increasing neurotransmission in regions where transmission of endogenous neurotransmitters is low, such as the prefrontal cortex in schizophrenia
* exerting little effect in regions where neurotransmitter activity is normal, such as the pituitary gland.
Cariprazine has higher binding affinity for dopamine D3 receptors (Ki 0.085 nM) than for D2L receptors (Ki 0.49 nM) and D2S receptors (Ki 0.69 nM). The drug also has strong affinity for serotonin receptor 5-HT2B; moderate affinity for 5-HT1A; and lower affinity for 5-HT2A, histamine HI, and 5-HT7 receptors. Cariprazine has little or no affinity for adrenergic or cholinergic receptors. (14)
In patients with schizophrenia, as measured on PET scanning, a dosage of 1.5 mg/d yielded 69% to 75% D2/D3 receptor occupancy. A dosage of 3 mg/d yielded >90% occupancy.
Search for an understanding of action continues. The relative contribution of D3 partial agonism, compared with D2 partial agonism, is a subject of ongoing basic scientific and clinical research. D3 is an autoreceptor that (1) controls phasic, but not tonic, activity of dopamine nerve cells and (2) mediates behavioral abnormalities induced by glutamate and N-methyl-Daspartate receptor antagonists. (5,12) In animal studies, D3-preferring agents have been shown to exert pro-cognitive effects and improve anhedonic symptoms.
Cariprazine is a once-daily medication with a relatively long half-life that can be taken with or without food. Dosages of 3 to 12 mg/d yield a fairly linear, dose-proportional increase in plasma concentration. The peak serum concentration for cariprazine is 3 to 4 hours under fasting conditions; taking the drug with food causes a slight delay in absorption but does not have a significant effect on the area under the curve. Mean half-life for cariprazine is 2 to 5 days over a dosage range of 1.5 to 12.5 mg/d in otherwise healthy adults with schizophrenia. (1)
Cariprazine is metabolized primarily by cytochrome P450 (CYP) 3A4. It is a weak inhibitor of CYP2D6 and CYP3A4. (1) Hepatic metabolism of cariprazine produces 2 active metabolites: desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR), both of which are equipotent to cariprazine. After multiple dose administration, mean cariprazine and DCAR levels reach steady state in 1 to 2 weeks; DDCAR, in 4 to 8 weeks. The systemic exposure and serum levels of DDCAR are roughly 3-fold greater than cariprazine because of the longer elimination half-life of DDCAR. (1)
Efficacy in schizophrenia
The efficacy of cariprazine in schizophrenia was established by 3 six-week, randomized, placebo-controlled trials. Two trials were fixed-dosage; a third used 2 flexible dosage ranges. The primary efficacy measure was change from baseline in the total score of the PANSS at the end of Week 6, compared with placebo. In all trials, patients were adults (age 18 to 60) who met DSMTV-TR criteria for schizophrenia and had a PANSS score between 80 and 120 at screening and baseline.
Study 1 (n = 711) compared dosages of 1.5 mg/d, 3 mg/d, and 4.5 mg/d with placebo.7 All cariprazine dosages and an active control (risperdone) were superior to placebo in reducing symptoms of schizophrenia, as measured by the PANSS. The placebo-subtracted differences on PANSS score at 6 weeks for dosages of 1.5 mg/d, 3 mg/d, and 4.5 mg/d were -7.6, -8.8, -10.4, respectively (significant at 95% CI). Study 2 (n = 151) compared 3 mg/d and 6 mg/d dosages of cariprazine with placebo. (1) Both dosages and an active control (aripiprazole) were superior to placebo in reducing PANSS scores. Placebo-subtracted differences on PANSS score at 6 weeks for dosages of 3 mg/d and 6 mg/day were -6.0, -8.8, respectively (significant at 95% CI).
Study 3 (n = 147) was a fixed-flexible dosage trial comparing cariprazine, 3 to 6 mg/d and 6 to 9 mg/d dosage ranges, to placebo. (8) Both ranges were superior to placebo in reducing symptoms on PANSS. Placebo-subtracted differences from placebo on PANSS at 6 weeks for cariprazine 3 to 6 or 6 to 9 mg/d were -6.8, -9.9, respectively (significant at 95% CI).
These trials established the efficacy of cariprazine for acute schizophrenia at dos ages ranging from 1.5 to 9 mg/d. Although there was a modest trend toward higher efficacy at higher dosages, there was a dose-related increase in certain adverse reactions (extrapyramidal symptoms [EPS]) at dosages >6 mg/d. (1)
Efficacy in bipolar disorder
The efficacy of cariprazine for acute treatment of manic or mixed episodes of BD I was established in 3 randomized, placebo-controlled, flexibly dosed 3-week trials. In all trials, patients were adults (age 18 to 65) who met DSM-TV-TR criteria for BD I with manic or mixed episodes and with or without psychotic features (YMRS score, [greater than or equal to] 20). The primary efficacy measure in the 3 trials was a change from baseline in the total YMRS score at the end of Week 3, compared with placebo.
Study 1 (n = 492) compared 2 flexibly dosed ranges of cariprazine (3 to 6 mg/d and 6 to 12 mg/d) with placebo. (10) Both dosage ranges were superior to placebo in reducing mixed and manic symptoms, as measured by reduction in the total YMRS score. Placebo-subtracted differences in YMRS scores from placebo at Week 3 for cariprazine 3 to 6 mg/d and 6 to 12 mg/d were -6.1, -5.9, respectively (significant at 95% CI). The higher range offered no additional advantage over the lower range.
Study 2 (n = 235) compared flexibly dosed cariprazine, 3 to 12 mg/d, to placebo. (11) Cariprazine was superior to placebo ' in reducing bipolar symptoms as measured by the YMRS. The difference between cariprazine 3 to 12 mg/d and placebo on the YMRS score at Week 3 was -6.1 (significant at 95% Cl).
Study 3 (n = 310) compared flexibly dosed cariprazine, 3 to 12 mg/d, with placebo. (15) Again, cariprazine was superior to placebo in reducing the YMRS score at Week 3: difference, -4.3 (significant at 95% CI).
These trials establish the efficacy of cariprazine in treating acute mania or mixed BD I episodes at dosages ranging from 3 to 12 mg/d. Dosages >6 mg/d did not offer additional benefit over lower dosages, and resulted in a dosage-related increase in EPS at dosages >6 mg/d. (16)
Cariprazine generally was well tolerated in short-term trials for schizophrenia and BD I. The only treatment-emergent adverse event reported for at least 1 treatment group in all trials at a rate of [greater than or equal to] 10%, and at least twice the rate seen with placebo was akathisia. Adverse events reported at a lower rate than placebo included EPS (particularly parkinsonism), restlessness, headache, insomnia, fatigue, and gastrointestinal distress. The discontinuation rate due to AEs for treatment groups and placebo-treated patients generally was similar. In schizophrenia Study 3, for example, the discontinuation rate due to AEs was 13% for placebo; 14% for cariprazine, 3 to 6 mg/d; and 13% for cariprazine, 6 to 9 mg/d. (1)
48-Week open-label safety study.
Patients with schizophrenia received open-label cariprazine for as long as 48 weeks. (7) Serious adverse events were reported in 12.9%, including 1 death (suicide); exacerbation of symptoms of schizophrenia (4.3%); and psychosis (2.2%). Treatment-emergent adverse events reported in at least 10% of patients included akathisia (14.0%), insomnia (14.0%), and weight gain (11.8%). The mean change in laboratory values, blood pressure, pulse rate, and electrocardiographic parameters was clinically insignificant.
Other Studies. In a 16-week, open-label extension study of patients with BD I, the major tolerability issue was akathisia. This AE developed in 37% of patients and led to a 5% withdrawal rate. (12)
In short- and long-term studies for either indication, the effect of the drug on metabolic parameters appears to be small. In studies with active controls, potentially significant weight gain (>7%) was greater for aripiprazole and risperidone than for cariprazine. (6,7) The effect on the prolactin level was minimal. There do not appear to be clinically meaningful changes in laboratory values, vital signs, or QT interval.
Unique clinical issues
Preferential binding. Cariprazine is the third dopamine partial agonist approved for use in the United States; unlike the other 2--aripiprazole and brexpiprazole--cariprazine shows preference for D3 receptors over D2 receptors. The exact clinical impact of a preference for D3 and the drug's partial agonism of 5-HT1A has not been fully elucidated.
EPS, including akathisia and parkinsonism, were among common adverse events. Both were usually mild, with 0.5% of schizophrenia patients and 2% of BD I patients dropping out of trials because of any type of EPS-related AEs.
Why Rx? On a practical medical level, reasons to prescribe cariprazine likely include:
* minimal effect on prolactin
* relative lack of effect on metabolic parameters, including weight (cariprazine showed less weight gain than risperidone or aripiprazole control arms in trials).
The recommended dosage of cariprazine for schizophrenia ranges from 1.5 to 6 mg/d. The recommended starting dosage is 1.5 mg/d, which can be increased to 3 mg on Day 2, with further upward dosage adjustments of 1.5 to 3 mg/d, based on clinical response and tolerability. (1)
The recommended dosages of cariprazine for mixed and manic episodes of BD I range from 3 to 6 mg/d. The recommended starting dosage is 1.5 mg/d, which can be increased to 3 mg on Day 2, with further upward dosage adjustments of 1.5 to 3 mg/d, based on clinical response and tolerability. (1)
Other key aspects of dosing to keep in mind:
* Because of the long half-life and 2 equipotent active metabolites of cariprazine, any changes made to the dosage will not be reflected fully in the serum level for 2 weeks.
* Administering the drug with food slightly delays, but does not affect, the extent of absorption.
* Because the drug is metabolized primarily by CYP3A4, dosage adjustment is required in the presence of a CYP3A4 inhibitor; the recommended starting dosage of cariprazine is 1.5 mg every other day with a maximum dosage of 3 mg/d when it is administered concomitantly with a strong CYP3A4 inhibitor.
* Because data are not available regarding concomitant use of cariprazine with a strong CYP3A4 inducer, this practice is not recommended. (1)
Cariprazine carries a FDA black-box warning of increased mortality in older patients who have dementia-related psychosis, as other atypical antipsychotics do. Clinical trials produced few data about the use of cariprazine in geriatric patients; no data exist about use in the pediatric population. (1)
Metabolic, prolactin, and cardiac concerns about cariprazine appeared favorably minor in Phase-III and long-term safety trials. Concomitant use of cariprazine with any strong inducer of CYP3A4 has not been studied, and is not recommended. Dosage reduction is recommended when using cariprazine concomitantly with a CYP3A4 inhibitor. (1)
The puzzle in neuropsychiatry has always been to find ways to produce different effects in different brain regions--with a single drug. Cariprazine's particular binding profile--higher affinity and higher selectivity for D3 receptors than for D2 receptors compared with either aripiprazole or brexpiprazole--may secure a role for it in managing psychosis and mood disorders.
Across clinical trials for both disorders, akathisia and parkinsonism were among more common AEs of cariprazine
Cariprazine is metabolized primarily by CYP3A4; it is a weak inhibitor ofCYP2D6and CYP3A4
Potentially significant weight gain (>7%) was greater for aripiprazole and risperidone than for cariprazine
Any changes made to the dosage will not be reflected fully in the serum level for 2 weeks
Cariprazine's particular binding profile may secure a role for it in managing psychosis and mood disorders
* Cutler AJ, Bose A, Durgam S, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week extension study. Poster presented at: 165th Annual Meeting of the American Psychiatric Association; May 5-9,2012; Philadelphia, PA.
Drug Brand Names
Aripiprazole * Abilify Brexpiprazole * Rexulti Cariprazine * Vraylar Risperdone * Risperdal
Cariprazine is the third dopamine-receptor partial agonist approved to treat schizophrenia and bipolar I disorder. The drug appears safe, is reasonably well tolerated, and has a generally favorable metabolic profile. The most troublesome adverse effect is akathisia, although the discontinuation rate in clinical trials because of akathisia was fairly small. The drug's binding profile is marked by higher affinity and higher selectivity for D3 receptors than for D2 receptors, compared with aripiprazole and brexpiprazole.
Gregory Mattingly, MD, and Richard Anderson, MD, PhD
(1.) Vraylar [package insert]. Parsippany, NJ: Actavis Pharma, Inc.; 2015.
(2.) McCormack PL, Cariprazine: first global approval. Drugs. 2015;75(17):2035-2043.
(3.) Kiss B, Horvath A, Nemethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(l):328-340.
(4.) Potkin, S, Keator, D, Mukherjee J, et al. P. 1. E 028 dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients. Eur Neuropsychopharmacology. 2009;19(suppl3):S316.
(5.) Veselinovic T, Paulzen M, Griinder G. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev Neurother. 2013;13(11):1141-1159.
(6.) Cutler A, Mokliatchouk O, Laszlovszky I, et al. Cariprazine in acute schizophrenia: a fixed-dose phase HI, randomized, double-blind, placebo- and active-controlled trial. Abstract presented at: 166th Annual Meeting of the American Psychiatric Association; May 18-22,2013; San Francisco, CA.
(7.) Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2-3):450-457.
(8.) Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367-373.
(9.) Bose A, Starace A, Lu, K, et al. Cariprazine in the treatment of acute mania in bipolar disorder: a double-blind, placebo-controlled, phase III trial. Poster presented at: 16th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists; April 21-24,2013; Colorado Springs, CO.
(10.) Calabrese JR, Keck PE Jr, Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284-292.
(11.) Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(l):63-75.
(12.) Ketter, T. A phase El, open-label, 16-week study of flexibly dosed cariprazine in 402 patients with bipolar I disorder. Presented at: 53rd Annual Meeting of the New Clinical Drug Evaluation Unit; May 28-31,2013; Hollywood, FL.
(13.) Bose A, Li D, Migliore R. The efficacy and safety of the novel antipsychotic cariprazine in the acute exacerbation of schizophrenia. Poster presented at: 50th Annual Meeting of the New Clinical Drug Evaluation Unit; June 14-17,2010; Boca Raton, FL.
(14.) Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013,*9(2):193-206.
(15.) Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296-302.
(16.) Vieta E, Durgam S, Lu K, et al. Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II/III trials. Eur Neuropsycholpharmacol. 2015;25(11):1882-1891.
Dr. Mattingly is Associate Clinical Professor and Psychopharmacology Instructor, Washington University in St. Louis, St. Louis, Missouri, and Founding Partner, Midwest Research Group, St. Charles, Missouri. Dr. Anderson is Clinical Instructor, Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, and Founding Partner, Midwest Research Group, St. Charles, Missouri.
The authors report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.
Table 1 Fast facts about cariprazine Brand name: Vraylar Class: Atypical antipsychotic Indications: Schizophrenia, bipolar I disorder FDA approval date: September 17,2015 Availability date: First quarter of 2016 Manufacturer: Allergan Dosing forms: 1.5 mg, 3 mg, 4.5 mg, and 6 mg capsules Recommended dosage: 1.5 to 6 mg/d (schizophrenia); 3 to 6 mg/d (bipolar I disorder) Table 2 Binding affinities of cariprazine Binding affinity Binding Receptor (nM Ki) profile D3 0.085 Partial agonist D2L 0.49 Partial agonist 5-HT2B 0.58 Antagonist D2S 0.69 Partial agonist 5-HT1A 2.6 Partial agonist 5-HT2A 18.8 Antagonist H1 23.2 Antagonist 5-HT7 111.0 Antagonist HT2C 134.0 Antagonist [alpha]-1 155.0 Antagonist Muscarinic >1,000.0 Antagonist
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Out of the Pipeline|
|Author:||Mattingly, Gregory; Anderson, Richard|
|Date:||Feb 1, 2016|
|Previous Article:||Chronic pain and psychiatric illness: managing comorbid conditions: pay close attention to risk and benefit when planning pain management.|
|Next Article:||Chronic pain and depression: understanding 2 culprits in common: does a shared pathophysiology hold the key to managing these conditions when they...|